Anzeige
Mehr »
Login
Dienstag, 21.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News! 22 Jahre "BlueChip"-Power nun bei NurExone!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P86D | ISIN: US45790W1080 | Ticker-Symbol:
NASDAQ
20.05.24
22:00 Uhr
4,730 US-Dollar
+0,130
+2,83 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INOZYME PHARMA INC Chart 1 Jahr
5-Tage-Chart
INOZYME PHARMA INC 5-Tage-Chart

Aktuelle News zur INOZYME PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.05.Inozyme Pharma Inc.: Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference1
08.05.Inozyme Pharma GAAP EPS of -$0.38 beats by $0.021
07.05.Inozyme Pharma Inc reports results for the quarter ended in March - Earnings Summary1
07.05.Inozyme Pharma Inc.: Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights99- Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024 - - Interim data from ENERGY-1, a Phase...
► Artikel lesen
07.05.Inozyme Pharma, Inc. - 10-Q, Quarterly Report-
07.05.Inozyme Pharma, Inc. - 8-K, Current Report1
03.05.Inozyme Pharma Inc.: Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)58BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
► Artikel lesen
08.04.Inozyme Reports Positive Topline Data From Phase 1/2 Study Of INZ-701; Stock Up3
08.04.Inozyme Pharma, Inc. - 8-K, Current Report1
08.04.Inozyme Pharma Inc.: Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency52- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study...
► Artikel lesen
06.04.Inozyme Pharma Inc.: Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)254BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
► Artikel lesen
02.04.Inozyme Pharma Inc.: Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference1
26.03.Inozyme Pharma Inc.: Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 20243
12.03.Inozyme Pharma: Q4 Earnings Insights1
12.03.Inozyme Pharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
12.03.Inozyme Pharma Inc.: Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights123- Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April - - Phase 1 trial of INZ-701 in end-stage kidney disease (ESKD)...
► Artikel lesen
12.03.Inozyme Pharma, Inc. - 10-K, Annual Report1
12.03.Inozyme Pharma, Inc. - 8-K, Current Report-
26.02.Inozyme Pharma Inc.: Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference1
06.02.Inozyme Pharma Inc.: Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)221BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
► Artikel lesen
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1